Bombardier Positions Challenger 3500 Business Jet Mockup in Olbia, Italy, For Customer Viewings Throughout the Summer

The Bombardier Challenger 3500 aircraft mockup The Bombardier Challenger 3500 business jet mockup is presented at the Costa Smeralda Airport in Olbia, Italy, after stops in Paris and Nice Full-size mockup is on display throughout the summer at the Sardinia FBO, showcasing to clients the Challenger 3500 award-winning cabin and exclusive Nuage seat Exceptional comfort, remarkable performance, and trusted […]

The Bombardier Challenger 3500 aircraft mockup
Bombardier Challenger 3500 aircraft mockup

Bombardier Positions Challenger 3500 Business Jet Mockup in Olbia, Italy, For Customer Viewings Throughout the Summer

  • The Bombardier Challenger 3500 business jet mockup is presented at the Costa Smeralda Airport in Olbia, Italy, after stops in Paris and Nice
  • Full-size mockup is on display throughout the summer at the Sardinia FBO, showcasing to clients the Challenger 3500 award-winning cabin and exclusive Nuage seat
  • Exceptional comfort, remarkable performance, and trusted reliability make the Challenger 3500 stand out as a leading choice in business aviation

OLBIA, Italy, July 08, 2024 (GLOBE NEWSWIRE) — Bombardier is excited to announce the presence of the Challenger 3500 aircraft mockup at the private terminal of the Costa Smeralda Airport in Olbia, Italy. Throughout the summer, business aviation clients will have a firsthand opportunity to experience the award-winning cabin and see the revolutionary seating of the super midsize jet. The journey of the full-size aircraft mockup included stops in Paris and Nice, France, and provides a convenient setting for European clients to discover the innovative and sophisticated features that make the Bombardier Challenger 3500 the leader in its class.

“The presence of the Bombardier Challenger 3500 mockup in a frequented travel destination such as Olbia is a testament to our commitment to providing a stress-free and easy access to product viewing,” said Emmanuel Bornand, Vice President, International Sales, Bombardier. “This is one of the many ways we make the business aviation experience unique. Every step of the way, we consistently tailor our services and support to meet our clients at their altitude, and that only comes from a genuine understanding of who they are and what they need. We are thankful to have this opportunity to showcase the amazing comfort, luxury and seamless technological features of the best-selling Challenger 3500 in the beautiful Sardinian FBO.”

The Challenger 3500 business jet, ‘’Best of the Best’’ laureate of the prestigious Red Dot Awards for Product Design, boasts the widest cabin in its class, providing passengers with an unparalleled sense of space and comfort. The custom-made cabin is a pinnacle of innovation and luxury, featuring the industry’s first integrated voice-controlled technology in its segment, 4K monitors, and Bombardier’s revolutionary Nuage seats that offer peerless comfort and support by mimicking the natural movements of the human body.

Designed with wellness in mind, the state-of-the-art aircraft has also the lowest cabin altitude in its class, standing at 4,850 feet, which significantly reduces passenger fatigue and enhances overall well-being. Advanced sound insulation contributes to a serene travel environment, allowing passengers to work, rest, or converse in peace.

The Challenger 3500 has an impressive range, capable of flying 3,400 nautical miles (6,297 kilometers), which allows the aircraft to fly out of Olbia to anywhere non-stop in Europe and in most sought-after cities of Africa and the Middle East, including Abu Dhabi, Lagos, Nairobi and Brazzaville. This remarkable range is complemented by the super midsize jet’s ability to operate in challenging airports around the world, thanks to its takeoff distance of 4,835 feet (1,474 meters) and a landing distance of 2,308 feet (703 meters).

The pilot-centric avionics suite of the Challenger 3500 ensures a seamless flight experience, and the overall aircraft performance capabilities can be trusted to offer a striking dispatch reliability rate of over 99.8%. With the lowest direct operating costs in its class, the Challenger 3500 represents reliability and value.

Guests of the Costa Smeralda Airport are welcome to visit the Bombardier Challenger 3500 mockup anytime without appointment throughout the months of July and August. Clients interested in discovering the super midsize jet can also book a private viewing by contacting the Bombardier Sales team.

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of approximately 5,000 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico.

For Information

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, as well as the company’s plans to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book and Claim system visit bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts
General media contact webform

Marie-Andrée Charron
+1-514-441-2598
marie-andree.charron@aero.bombardier.com

BombardierChallengerChallenger 3500 and Nuage are trademarks of Bombardier Inc. or its subsidiaries.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f880a97-5cc5-45fa-b468-d6e99980704f

GlobeNewswire Distribution ID 9174356

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe. […]

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe.

HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1

Following European Commission approval, HEMGENIX® was the first ever therapy to be granted Direct Access in France2, thus enabling the first patients to be treated in Europe outside of the clinical program.

Though effective, current therapies can be time intensive and require regular treatment that can have a substantial impact on a patient’s daily life.3 HEMGENIX® offers a one-time treatment, allowing people living with hemophilia B to produce their own Factor IX, which can lower the risk of bleeding.4

“Only a few decades ago, gene therapy for hemophilia was a distant concept, which has now become reality. Accordingly, the first two patients treated with HEMGENIX® since receiving European approval is a major accomplishment and a testament to the joint commitment of the hemophilia B community, as well as the access and reimbursement authorities, in bringing innovative therapies to patients,” said Dr Lutz Bonacker SVP and General Manager, CSL Behring Commercial Operations Europe. “This milestone has been made possible by the innovative Direct Access scheme adopted in France, allowing patients to benefit from early access to pioneering treatments. We are encouraged to see increasing access to gene therapies in European countries and are fully committed to ensuring that access to potentially life-changing treatment continues.”

HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022. It has also been approved by Health Canada, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), Switzerland’s Swissmedic and Australia’s Therapeutic Goods Administration (TGA).

The multi-year clinical development of HEMGENIX® was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment.

About Hemophilia B

Hemophilia B is a life-threatening rare disease. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Current treatments for moderate to severe hemophilia B include life-long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor.

About HEMGENIX®

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

About the Pivotal HOPE-B Trial

The pivotal Phase III HOPE-B trial is an ongoing, multinational, open-label, single-arm study to evaluate the safety and efficacy of HEMGENIX®. Fifty-four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six-month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six-month lead-in period, patients received a single intravenous administration of HEMGENIX® at the 2×10^13 gc/kg dose. Patients were not excluded from the trial based on pre-existing neutralizing antibodies (NAbs) to AAV5.

A total of 54 patients received a single dose of HEMGENIX® in the pivotal trial, with 52 patients completing at least three years of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six-month lead-in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady-state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

No serious treatment-related adverse reactions were reported. One death resulting from urosepsis and cardiogenic shock in a 77-year-old patient at 65 weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined to be unrelated to treatment with HEMGENIX® by independent molecular tumour characterization and vector integration analysis. No inhibitors to factor IX were reported.

Long-term three-year data presented at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2024 continue to reinforce the potential long-lasting efficacy and safety of HEMGENIX® and the ongoing benefit of this treatment for people living with hemophilia B.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

Media Contacts
Stephanie Fuchs
Mobile: +49 151 584 388 60
Email: Stephanie.Fuchs@cslbehring.com

References


1 European Medicines Agency. First Gene therapy to treat haemophilia B. Available at: https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b. [Accessed May 2024].
2 Republique Française. Légifrance: Article 62 of Law No. 2021-1754. Available at: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048551003 [Accessed May 2024].
3 Leebeek, F & Miesbach, W. (2021) Gene therapy for haemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. Vol 138, Issue 11. pp923-931.
4 Coppens M et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. The Lancet Haematology 2024; 11(4):E265-E275.

GlobeNewswire Distribution ID 1000969961

Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea […]

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank

Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (“OSA”), today announced that it has signed a €37.5 million loan facility agreement with the European Investment Bank (“EIB”). The agreement is backed by the European Commission’s InvestEU program. Nyxoah plans to use the funding for research and development, and for scaling-up its manufacturing capacity to meet demand in Europe and the U.S.

The €37.5 million facility is divided into three tranches: €10 million for the first tranche (“Tranche A”), €13.75 million for the second tranche (“Tranche B”) and €13.75 million for the third tranche (“Tranche C”). Disbursement under the various tranches is subject to certain conditions. Tranche A carries an annual 5% cash and 5% capitalized interest rate, and features a five-year bullet repayment schedule. The various tranches do not contain revenue or liquidity covenants.

In connection with the loan facility agreement, and as a condition to drawdown thereunder, the Company also intends to enter into a “synthetic warrant agreement” with the EIB. Under the intended synthetic warrant agreement, in consideration for the facility, in connection with each tranche of the facility, the EIB will be granted “synthetic warrants” with a duration of 20 years. The number and strike price of the synthetic warrants will be calculated based on tranche specific formulas provided for in the synthetic warrant agreement. The synthetic warrants can be exercised as of the maturity date of the relevant tranche of the facility or, in exceptional situations, earlier. Such synthetic warrants will entitle the EIB to receive from the Company a cash consideration equal to the 20-day volume weighted average price of a share in the Company on the stock exchange, reduced by the applicable strike price per synthetic warrant, and multiplied by the number of synthetic warrants that the EIB exercises. In connection with Tranche A, it is expected that the EIB will be granted 468,384 synthetic warrants with a strike price of €8,11 that the EIB can exercise after the maturity of Tranche A (5 years) or, in exceptional situations, earlier.

Since certain provisions of the loan facility agreement and the synthetic warrant agreement are dependent on a change of control, those provisions will be submitted for approval to a shareholders’ meeting of the Company in accordance with article 7:151 of the Belgian Companies and Associations Code.

EIB Vice-President Robert de Groot said: “Belgium stands at the forefront of innovation in the area of life sciences and med tech. As the EIB, we take pride in supporting this thriving industry and fostering growth. Nyxoah, with its groundbreaking approach, is making a valuable contribution. We are eager to see the company progressing, benefitting patients worldwide.”

Olivier Taelman, CEO of Nyxoah, commented: “We are excited and grateful for the support and confidence in our cutting-edge technology shown by the European Investment Bank. This loan follows our recent successful equity offering where we raised €48.5 million, providing us a combined access to over €80 million in growth capital. This will aid in the commercialization of Genio in Europe and in the U.S., if approved, while helping increase production capacity and sustain innovation.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please see the Company’s annual report for the financial year 2023 and visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the entry into of the loan facility agreement and the synthetic warrant agreement with the EIB; the use of proceeds from the loan facility agreement; the Genio® system and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; reporting data from Nyxoah’s DREAM U.S. pivotal trial; filing for FDA approval; and entrance to the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

For Media
Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc-services.eu

Attachment

GlobeNewswire Distribution ID 1000969769

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands Apparel Group hosted a lifestyle shoot in partnership with Anantara The Palm Resort, showcasing their summer collections that are available in store and on 6thstreet.com. Celebrating Summer Time with Apparel Group Brands – Aldo, Aldo Accessories, Ardene, Asics, Athlete’s Co., Beverly […]

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

  • Apparel Group hosted a lifestyle shoot in partnership with Anantara The Palm Resort, showcasing their summer collections that are available in store and on 6thstreet.com.
  • Celebrating Summer Time with Apparel Group Brands – Aldo, Aldo Accessories, Ardene, Asics, Athlete’s Co., Beverly Hills Polo Club, Birkenstock, Calvin Klein, Charles & Keith, Cold Stone Creamery, Crocs, Dune London, F5 Global, Forest Essentials, Forever New, Havaianas, Herschel, Inglot, Jamie’s Italian, La Vie En Rose, LC Waikiki, LCW Home, New Yorker, Nine West, Not Ordinary, Nysaa, R&B Kids, Rituals, Skechers, Steve Madden, The Children’s Place, Tim Hortons and Tommy Hilfiger

DUBAI, United Arab Emirates, July 03, 2024 (GLOBE NEWSWIRE) — Apparel Group, a leading retail and lifestyle conglomerate, is excited to announce the release of their newest Summer Time campaign showcasing summer collections from more than 36 Apparel Group brands. In collaboration with Anantara The Palm Resort, this lifestyle shoot combines the fashion-forward expertise of Apparel Group with the luxurious ambiance and pristine settings, promising a summer collection that redefines style and elegance.

Mrs. Sima Ganwani Ved, Founder and Chairwoman of Apparel Group, expressed her enthusiasm for the launch, stating, “We are so excited to share Apparel Group’s summer look-book for 2024, with over 36 of Apparel Group international and home grown brands, each bringing their unique flair to this exciting season. This summer campaign is not just about showcasing our summer collection but creating a lifestyle experience that resonates with our customers.”

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

Apparel Group Launches Exciting ‘Summer-Time’ Campaign 2024 Featuring More than 36 of Their Brands

The summer campaign features a stellar lineup of Apparel Group’s celebrated international and home grown brands, including Aldo, Aldo Accessories, Ardene, Asics, Athlete’s Co., Beverly Hills Polo Club, Birkenstock, Calvin Klein, Charles & Keith, Cold Stone Creamery, Crocs, Dune London, F5 Global, Forest Essentials, Forever New, Havaianas, Herschel, Inglot, Jamie’s Italian, La Vie En Rose, LC Waikiki, LCW Home, New Yorker, Nine West, Not Ordinary, Nysaa, R&B Kids, Rituals, Skechers, Steve Madden, The Children’s Place, Tim Hortons and Tommy Hilfiger. Each brand will bring its unique style and flair, offering everything from casual chic to summer glamour. The collection promises to cater to a wide range of style preferences, ensuring there is something special for everyone.

Customers eager to embrace the summer vibes can look forward to shopping the collection on Apparel Group store outlets and e-commerce platform, 6thStreet.com, where the full range of products will be available. Blending retail innovation with luxury hospitality, this campaign highlights the synergy between Apparel Group and Anantara The Palm Resort catering to residents and tourists positioning the region as the ultimate summer destination.

Stay tuned for a summer of style, sophistication, and scenic beauty, exclusively brought to you by Apparel Group and Anantara The Palm Resort.

ABOUT APPAREL GROUP LLC

Apparel Group is a global fashion and lifestyle retail conglomerate residing at the crossroads of the modern economy – Dubai, United Arab Emirates. Today, Apparel Group caters to thousands of eager shoppers through its 2200+ retail stores and 85+ brands on all platforms while employing over 22,000+ multicultural staff.

Apparel Group has carved its strong presence in the GCC and expanded thriving gateways to market in India, South Africa, Singapore, Indonesia, Thailand, Malaysia, and Egypt. Additionally, clear strategies are in place to enter emerging markets such as Hungary and Philippines.

Apparel Group has created an omni-channel experience, operating brands originating from the USA, Canada, Europe, Australia, and Asia. The brands include leading names in fashion, footwear, and lifestyles such as Tommy Hilfiger, Charles & Keith, Skechers, Aldo, Nine West, Aeropostale, Jamie’s Italian, Tim Hortons, Cold Stone Creamery, Inglot, and Rituals.

Apparel Group owes its amazing growth to the vision and guidance of its dynamic Founder and Chairwoman, Mrs. Sima Ganwani Ved, who has taken the company from strength to strength since its inception in the last two decades.

https://apparelglobal.com/en/
PR@apparelglobal.com

About Anantara The Palm Resort

Anantara is a luxury hospitality brand for modern travellers, connecting them to genuine places, people and stories through personal experiences, and providing heartfelt hospitality in the world’s most exciting destinations. The collection of distinct, thoughtfully designed luxury hotels and resorts provides a window through which to journey into invigorating new territory, curating personal travel experiences.

From cosmopolitan cities to desert sands to lush islands, Anantara connects travellers to the indigenous, grounds them in authentic luxury, and hosts them with passionate expertise. The portfolio currently boasts over 40 stunning hotels and resorts located in Thailand, Maldives, Indonesia, Vietnam, China, Cambodia, Malaysia, Sri Lanka, Mauritius, Seychelles, Mozambique, Zambia, UAE, Qatar, Oman, Tunisia, Portugal, Spain, Hungary, The Netherlands, Italy, Ireland and France, with a pipeline of future properties across Asia, the Middle East, Europe and South America.

For more information on Anantara Hotels, Resorts & Spas, please visit www.anantara.com

Follow us on Facebook: www.facebook.com/anantara; Twitter and Instagram: @anantara_hotels

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/3c050648-49b9-4720-bd36-03eee8be5739

https://www.globenewswire.com/NewsRoom/AttachmentNg/30b0f74f-7194-40d2-9530-8abe169e79c0

GlobeNewswire Distribution ID 9172820

‫مجموعة أباريل تطلق حملة ” موسم الصيف” لعام 2024 بمشاركة أكثر من 36 علامة تجارية تابعة لها

مجموعة أباريل تطلق حملة ” موسم الصيف” لعام 2024 بمشاركة أكثر من 36 علامة تجارية تابعة لها استضافت مجموعة أباريل جلسة تصوير بالتعاون مع فندق أنانتارا النخلة، حيث عرضت من خلالها التشكيلات الصيفية المتوفرة في المحلات وعبر المتجر الإلكتروني 6thstreet.com. احتفالاً بموسم الصيف مع علامات مجموعة أباريل – ألدو، ألدو إكسسوارات، أردين، اسيكس، أثليتسكو، بفرلي هيلس بولو […]

مجموعة أباريل تطلق حملة ” موسم الصيف” لعام 2024 بمشاركة أكثر من 36 علامة تجارية تابعة لها

مجموعة أباريل تطلق حملة ” موسم الصيف” لعام 2024 بمشاركة أكثر من 36 علامة تجارية تابعة لها

  • استضافت مجموعة أباريل جلسة تصوير بالتعاون مع فندق أنانتارا النخلة، حيث عرضت من خلالها التشكيلات الصيفية المتوفرة في المحلات وعبر المتجر الإلكتروني 6thstreet.com.
  • احتفالاً بموسم الصيف مع علامات مجموعة أباريل – ألدو، ألدو إكسسوارات، أردين، اسيكس، أثليتسكو، بفرلي هيلس بولو كلوب، بيركنستوك، كلفن كلاين، تشارلز&كيث، كولدستون كريمري، كروكس، ديون لندن، أف فايف، فورست اسينشيالز، فورايفر نيو، هافايانس، هيرشل، إنجلوت، جيميز إتاليان، لافي إن روز، إل سي واي كيكي، إل سي دبليو هوم، نيويوركر، ناين وست، نوت أورديناري، نساء، آر آند بي الأطفال، ريتوالز، سكتشرز، ستيف مادن، ذا تشيلدرنز بليس، تيم هورتنز وتومي هيلفيغر.

دبي، الإمارات العربية, July 03, 2024 (GLOBE NEWSWIRE) — بكل حماس تعلن مجموعة أباريل الرائدة في مجال البيع بالتجزئة وأسلوب الحياة، عن حملة موسم الصيف الجديدة كلياً وتعرض من خلالها تشكيلات الصيف لأكثر من 36 علامة تجارية تابعة لها. إذ أتمت جلسة تصوير مميزة بالتعاون مع فندق أنانتارا النخلة، مجسدةً الرؤية المعاصرة لمجموعة أباريل من خلال عرض الأجواء الفاخرة في إطار مميز، وتعد بتشكيلة صيفية تجدد معنى الأناقة الصيفية الراقية.

علقت السيدة سيما جانواني فيد، مؤسسة ورئيسة مجموعة أباريل مشيرةً إلى سعادتها الغامرة بهذه الحملة بقولها: ” نحن في غاية الحماس لمشاركة الدليل الصيفي الرسمي من مجموعة أباريل لعام 2024، ونقدم من خلاله لمستنا الفريدة لهذا الموسم الرائع عبر أكثر من 36 علامة تجارية عالمية ومحلية تابعة لمجموعة أباريل. حملة الصيف هذه لا تقتصر على عرض تشكيلاتنا الصيفية فحسب، بل نسعى من خلالها إلى الترويج لأسلوب حياة مميز ومبتكر بين عملائنا”.

تضم الحملة الصيفية مجموعة رائعة من العلامات التجارية العالمية والمحلية الأبرز لدى مجموعة أباريل بما فيها ألدو وألدو إكسسوارات وأردين واسيكس وأثليتسكو وبفرلي هيلس بولو كلوب وبيركنستوك وكلفن كلاين وتشارلز & كيث وكولدستون كريمري وكروكس وديون لندن وأف فايف وفورست اسينشيالز وفورايفر نيو وهافايانس وهيرشل وإنجلوت وجيميز إتاليان ولافي إن روز وإل سي واي كيكي و إل سي دبليو هوم ونيويوركر وناين وست ونوت أورديناري ونساء وآر آند بي الأطفال وريتوالز وسكتشرز وستيف مادن وذا تشيلدرنز بليس وتيم هورتنز وتومي هيلفيغر. حيث تضفي كل علامة تجارية أسلوباً مميزاً وطابعاً فريداً وكل ما يزيد الصيف تألقاً من خلال اختيارات أنيقة وعملية. وتعد هذه التشكيلة بتوفير خيارات واسعة ومتنوعة تناسب كافة الأذواق، وتلبي احتياجات الجميع بلمسة مميزة وفريدة.

مجموعة أباريل تطلق حملة ” موسم الصيف” لعام 2024 بمشاركة أكثر من 36 علامة تجارية تابعة لها

مجموعة أباريل تطلق حملة ” موسم الصيف” لعام 2024 بمشاركة أكثر من 36 علامة تجارية تابعة لها

سيتثنى للمتسوقين المقبلين بحماس على أجواء الصيف الممتعة، الحصول على التشكيلات من محلات علامات مجموعة أباريل وعبر المتجر الإلكتروني 6thstreet.com إذ سيتم من خلالها طرح المجموعة الكاملة من المنتجات في الأسواق. وحيث أن هذه الحملة تجمع بين الابتكار في مجال البيع بالتجزئة و الوجهات الترفيهية الفاخرة، فهي تسلط الضوء على الجهود المشتركة بين مجموعة أباريل وفندق أنانتارا النخلة، من أجل تلبية احتياجات المقيمين والسياح بما يجعل المنطقة وجهة صيفية مثلى.

ترقبوا الصيف المليء بالأناقة والجمال والفخامة الذي تعدكم به مجموعة أباريل وفندق أنانتارا النخلة.

لمحة عن مجموعة أباريل

تقف مجموعة أباريل، أكبر مشغل في مجالات الأزياء وأسلوب الحياة، على مفترق طرق الاقتصاد الحديث في مدينة دبي، بدولة الإمارات العربية المتحدة. واليوم، أضحت المجموعة قادرة على تلبية احتياجات ملايين المتسوقين عبر أكثر من 2,200 متجراً وأكثر من 85 علامة تجارية وبتعيين 22,000 موظف من مختلف الثقافات.

حققت المجموعة حضوراً قوياً وراسخاً في دول مجلس التعاون الخليجي كما أنها نجحت في توسيع مجالات تسويقها في الهند وجنوب أفريقيا وسنغافورة واندونيسيا وتايلند وماليزيا ومصر. وإضافة إلى ذلك، وضعت المجموعة استراتيجيات واضحة للدخول إلى العديد من الأسواق الناشئة مثل هنغاريا والفليبين.

تدير مجموعة أباريل العديد من العلامات التجارية العالمية الشهيرة، التي انطلقت من الولايات المتحدة الأمريكية وكندا وأوروبا وأستراليا وآسيا، وتضم الكثير من الأسماء الرائدة في عالم الأزياء، الأحذية ونمط الحياة على غرار تومي هيلفيغر، تشارلز آند كيث، سكتشرز، ألدو، ناين وست، إروبوستال، وغيرها من الأسماء بالإضافة لعلامات تجارية رئيسية مثل تيم هورتنز، جيميز اتاليان، كولدستون كريمري، إنجلوت، ريتوالز وذلك على سبيل المثال لا الحصر.

يذكر بأن الفضل في نجاحات مجموعة أباريل ونموها المذهل يعود لرؤية وتوجيهات مؤسستها ورئيسة مجلس الإدارة سيما جنواني فيد، التي انطلقت بالشركة من القوة إلى الأقوى منذ نشأتها وعلى امتداد عقدين من الزمن

https://apparelglobal.com/ar/
PR@apparelglobal.com

لمحة عن فندق أنانتارا النخلة

أنانتارا هي علامة فاخرة في مجال خدمات الضيافة للسياح المعاصرين، ذات رؤية هادفة لربط الأشخاص بالأماكن والقصص من خلال التجارب الشخصية المبتكرة، وتوفر لهم أعلى معايير الضيافة في أكثر الوجهات العالمية تميزاً. توفر مجموعة الفنادق والمنتجعات الفاخرة المصممة بدقة مدروسة بوابة واسعة لاستكشاف معالم جديدة وتجربة رحلات شخصية ممتعة                                                 

تربط أنانتارا المسافرين بالسكان المحليين في جميع الوجهات بما فيها من مدن عالمية إلى وجهات صحراوية وجزر سياحية، وتمنحهم الرفاهية الأصيلة من خلال خدماتها التي تقدمها بشغف وخبرةوتضم مجموعة الفنادق حالياً أكثر من 40 فندقاً ومنتجعاً رائعاً في تايلاند وجزر المالديف وإندونيسيا وفيتنام والصين وكمبوديا وماليزيا وسريلانكا وموريشيوس وجزر سيشل وموزمبيق وزامبيا والإمارات العربية المتحدة وقطر وعُمان وتونس والبرتغال واسبانيا والمجر وهولندا وإيطاليا وإيرلندا وفرنسا وفي عدد من المواقع المستقبلية في سائر أنحاء آسيا والشرق الأوسط وأوروبا وأمريكا الجنوبية.

للمزيد من المعلومات عن فنادق ومنتجعات وسبا أنانتارا، يرجى زيارة www.anantara.com

ومتابعة حساباتنا عبر فيسبوك: www.facebook.com/anantara وتويتر وانستغرام:@anantara_hotels

الصورة المصاحبة لهذا الإعلان متاحة على
https://www.globenewswire.com/NewsRoom/AttachmentNg/3c050648-49b9-4720-bd36-03eee8be5739/ar

الصورة المصاحبة لهذا الإعلان متاحة على
https://www.globenewswire.com/NewsRoom/AttachmentNg/30b0f74f-7194-40d2-9530-8abe169e79c0/ar

GlobeNewswire Distribution ID9172820

DigiAsia Corp. Announces Completion of Convertible Note Financing with Helena Partners and Extinguishes Outstanding Debt

~ Prompt Extinguishment of Debt Following Recent Listing as a Public Company Prioritizes Financial Responsibility with a Healthy Capital Structure ~ NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) — DigiAsia Corp. (NASDAQ: FAAS) (“DigiAsia” or the “Company”), a leading Fintech as a Service (“FaaS”) ecosystem provider, today announced it has received net proceeds of $3.0 […]

~ Prompt Extinguishment of Debt Following Recent Listing as a Public Company Prioritizes Financial Responsibility with a Healthy Capital Structure ~

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) — DigiAsia Corp. (NASDAQ: FAAS) (“DigiAsia” or the “Company”), a leading Fintech as a Service (“FaaS”) ecosystem provider, today announced it has received net proceeds of $3.0 million as a result of the previously announced Securities Purchase Agreement (“SPA”) with Helena Special Opportunities LLC, an affiliate of Helena Partners Inc. (“Helena”). In addition, through the issuance of Senior Unsecured Convertible Notes (the “Notes”), convertible into Class A common shares of the Company, and $5.2 million of Class B Convertible Notes, DigiAsia has extinguished all debt inherited from its business combination with StoneBridge Acquisition Corporation. The remainder of proceeds will be utilized for general corporate purposes as growth capital investment.

As announced on June 21, 2024, the Notes bear interest at a rate of 12% per annum, payable quarterly, and mature one year from the issuance of the note. Helena, pursuant to its note, has the option, on or prior to the maturity date, to convert the entire principal amount and all accrued but unpaid interest on the notes into shares of DigiAsia common stock.

EF Hutton LLC acted as the exclusive placement agent for the offering. Winston & Strawn LLP acted as legal advisor to DigiAsia.

Forward-Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that may be deemed forward-looking statements. These forward-looking statements including, but not limited to, statements concerning DigiAsia and the Company’s operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. DigiAsia cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world including those discussed in DigiAsia’s Form 20-F under the headings “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time. All forward-looking statements are applicable only as of the date it is made and DigiAsia specifically disclaims any obligation to maintain or update the forward-looking information, whether of the nature contained in this release or otherwise, in the future.

DigiAsia Company Contact:

Subir Lohani

Chief Financial Officer and Chief Strategy Officer

646-480-0142

Investor Contact:

MZ North America

Email: FAAS@mzgroup.us

GlobeNewswire Distribution ID 9172144